Council of Scientific and Industrial Research

Ravinder Singh Jolly

Javed Naim Agrewala

Suneet Kaur

Rakesh Mulraj Vohra

Gautam Srivastava

Arvind Kumar Singla

The present invention is to provide a preparation of variant recombinant whole cell biocatalysts, referred herein as 'designer cells' having significantly enhanced carbonyl reductase activity for use in the efficient production of variant industrially important enantiomerically enriched alcohols. More specifically, the alcohol is optically pure ethyl (S)-4-chloro-3-hydroxybutyrate, which is useful as chiral building block and an intermediate for the production of hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors.

Designer cells for enantioselective reduction of ketones and use thereof in efficient production of enantioenriched alcohols

The present invention relates to an isolated bioactive molecule Caerulomycin A, derivatives and analogs thereof as effective immunosuppressive agents. The immunosuppressive property of the compound is targeted in particular against the lymphocytes, CD4T cells, CD8T cells and B cells and in the production of IL-4 and IFN-&#x3b3; and antibodies. The compound operates through a mechanism by downregulating the expression of activation marker CD28 and upregulating the immunosuppressive marker CTLA-4. Caerulomycin A has previously been isolated fromand found to have useful antifungal activity. Prior to the present invention however, this compound had not been determined to have immunomodulatory activity.

Growing community of inventors

Chandigarh, India

Ravinder Singh Jolly